Sinopharm Group Co. Ltd. — Regulatory Filings 2012

Oct 25, 2012

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [58 x 71] intentionally omitted <==

SINOPHARM GROUP CO. LTD.[*] 國藥控股股份有限公司

(A joint stock limited company incorporated in the People’s Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司 )

(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL FINANCIAL DATA AND INDICATORS OF SINOPHARM (CNCM LTD) FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2012

Reference is made to the overseas regulatory announcement dated 25 October 2012 (the “ Announcement ”) and issued by Sinopharm Group Co. Ltd. (the “ Company ”) in relation to the third quarterly report for the nine months ended 30 September 2012 of China National Medicines Corporation Ltd. (“ SINOPHARM (CNCM LTD) ”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data and indicators of SINOPHARM (CNCM LTD) for the nine months ended 30 September 2012 as set out in the Announcement.

PRINCIPAL FINANCIAL DATA AND INDICATORS OF SINOPHARM (CNCM LTD)

Unit: Yuan Currency: RMB

			Increase/
			decrease at
			the end of the
	As at		reporting period
	the end of	As at	as compared to
	the reporting	the end of	the end of
	period	last year	last year (%)
Total assets (RMB)	4,263,137,002.39	3,551,673,504.85	20.03
Ow ners’ equity interest (or shareholders’
equity interest) (RMB)	1,735,507,780.50	1,488,975,184.18	16.56
Ne t assets per share attributable to the
shareholders of listed company (RMB/Share)	3.6247	3.1098	16.56

1

				Increase/
	From the beginning			decrease
	of the year to the			compared to
	end of the	reporting		the corresponding
	period (January to			period of
	September)			last year (%)
Net cash flow arising from operating
activities (RMB)	106,327,729.99			N/A
Net cash flow arising from operating
activities per share (RMB/Share)		0.2221		N/A
				Increase/
			From	decrease during
		the beginning		the reporting
		of the	year to	period as
		the end of		compared to the
	The reporting	the reporting		corresponding
	period (July to	period (January		period of
	September)	to September)		last year (%)
Ne t profit attributable to the shareholders
of listed company (RMB)	104,715,334.76	273,390,066.76		23.13
Basic earnings per share (RMB/Share)	0.2187		0.5710	23.13
Ba sic earnings per share after deducting
non-recurring gains or losses
(RMB/Share)	0.2180		0.5695	37.14
Diluted earnings per share (RMB/Share)	0.2187		0.5710	23.13
				Increased by 0.24
Weighted average return on equity (%)	6.22		16.96	percentage points
We ighted average return on equity after
deducting non-recurring gains and				Increased by 0.85
losses (%)	6.20		16.91	percentage points

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board Sinopharm Group Co. Ltd. She Lulin Chairman

Shanghai, the PRC 25 October 2012

As at the date of this announcement, the executive director of the Company is Mr. Wei Yulin; the non-executive directors of the Company are Mr. She Lulin, Mr. Wang Qunbin, Mr. Chen Wenhao, Mr. Zhou Bin, Mr. Chen Qiyu, Mr. Deng Jindong, Mr. Fan Banghan and Mr. Liu Hailiang; and the independent non-executive directors of the Company are Mr. Wang Fanghua, Mr. Tao Wuping, Mr. Xie Rong and Mr. Zhou Bajun.

• The Company is registered as a non-Hong Kong company under Part XI of the Companies Ordinance (Chapter 32 of the Laws of Hong Kong) under its Chinese name and the English name “Sinopharm Group Co. Ltd.”

2